


Winter 2021



Publication date: 2 December, 2021

European Biotechnology Life Sciences and Industry Magazine

# Gene & Cell Therapies Get on Board!

#### Hot topics in gene & cell therapies and vaccines

The past five years have been a critical turning point for gene and cell therapies. From the first approved oligonucleotide-based therapy to the success of CAR-T cell therapies, followed by the recent in-vivo gene therapies and the emerging gene editing strategies, these gene therapeutics and its mRNA-based vaccine couterparts are not only life-changing for patients with rare diseases, but are also laying the foundation for potential treatments of other unmet medical needs. For experts in vector engineering, analytics, preclinical development, and clinical translation to help accelerate next generation gene and cell therapy development a golden decade has broken in a time when COVID-19 vaccine manufacturing has significantly impacted the supply chains of producers of mRNA gene therapies and vector-based vaccines.

### **Present your expertise**

CDMOs, vector providers, experts in transfection and expression vectors as well as ATMP developers will have the opportunity to present their latest products, services, and equipment in this special. EUROPEAN BIO-TECHNOLOGY goes out to decision makers throughout the entire European Life Sciences sector. Take advantage of to the journal's highly relevant readership and grab this opportunity to target your audience!

### Topics to be covered

**Gene & Cell therapies and vaccines:** vaccine vs gene & cell therapy vectors (lentiviral, AAV vectors), mRNA therapeutics/vaccines, CAR-T cell therapies, gene & cell therapy hubs, GMP-compliant process development/scale up, single use equipment vs stainless steel, media/cell line development, formulation, preclinical & clinical testing, fill & finish, process development automation, gene and cell therapies

## Editorial Deadline 17-11-2021

Editorial Contact: Thomas Gabrielczyk Tel.: +49-1575-0977232 Fax: +49-30-264921-11 t.gabrielczyk@biocom.de

#### Booking Deadline 19-11-2021

Marketing Contact: Oliver Schnell Tel.: +49-30-264921-45 Fax: +49-30-264921-11 o.schnell@biocom.de

### Publication Date 02-12-2021

Marketing Contact: Andreas Macht Tel.: +49-30-264921-54 Fax: +49-30-264921-11 a.macht@biocom.de



## Special: Gene & Cell Therapies and Vaccines Meet your audience!

### European Biotechnology is published in co-operation with the following organisations:



EUROPEAN BIOTECHNOLOGY covers the biotechnology sector of the current 27 EU member states, Norway, Switzerland, and UK. If you would like to subscribe, please refer to **european-biotechnology.com**.